Internal Medicine, Rheumatology · Brockton, MA
NPI
1730155029
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
4
Medicare group memberships
Hospitals
5
Hospital affiliations
1351 Main St, Rear
Brockton, MA, 02301
Phone (508) 587-4112
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.8M
166,145 services
Medicare patients, 2024
885
Average age 73
Drug cost, 2024
$7.2M
9,907 prescriptions
Company payments, 2025
$33K
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Raphael I Kieval was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 50,800 times for 22 patients. In total Raphael I Kieval billed 166,145 services in 50 codes, and Medicare paid $1.8M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-24.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 50,800 | 22 | $3.62 | $184K |
| J3262 Injection, tocilizumab, 1 mg | Office | 33,160 | 12 | $4.70 | $156K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 19,740 | 19 | $8.59 | $170K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 17,900 | 36 | $8.77 | $157K |
| J0897 Injection, denosumab, 1 mg | Office | 12,480 | 132 | $20.21 | $252K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 9,775 | 16 | $33.87 | $331K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,740 | 24 | $0.10 | $168 |
| J9312 Injection, rituximab, 10 mg | Office | 1,610 | 12 | $61.08 | $98K |
| 99214 Office E&M - Established | Office | 641 | 401 | $91.85 | $59K |
| 96401 Chemotherapy Administration | Office | 571 | 170 | $53.65 | $31K |
| 99213 Office E&M - Established | Office | 566 | 389 | $65.07 | $37K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 549 | 347 | $11.56 | $6,348 |
| 96413 Chemotherapy Administration | Office | 411 | 97 | $103.57 | $43K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 311 | 72 | $0.48 | $149 |
| 96415 Chemotherapy Administration | Office | 118 | 29 | $21.60 | $2,548 |
By year: 2022 $1.7M for 141,293 services; 2023 $1.7M for 148,916 services; 2024 $1.8M for 166,145 services.
Medicare prescription drug claims, 2024
In 2024, the drug Raphael I Kieval prescribed most often to Medicare patients was Celecoxib, with 953 prescriptions and refills. In total Raphael I Kieval wrote 9,907 Medicare prescriptions that cost $7.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Celecoxib Generic | 953 | 1,513 | 202 | $42K |
| Prednisone Generic | 931 | 1,301 | 202 | $5,766 |
| Tramadol Hcl Generic | 698 | 728 | 137 | $5,025 |
| Methotrexate Methotrexate Sodium | 679 | 1,302 | 146 | $19K |
| Hydroxychloroquine Sulfate Generic | 677 | 1,133 | 141 | $19K |
| Meloxicam Generic | 586 | 915 | 121 | $2,398 |
| Gabapentin Generic | 515 | 693 | 81 | $8,063 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 451 | 451 | 70 | $9,554 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 302 | 302 | 49 | $5,993 |
| Cyclobenzaprine Hcl Generic | 220 | 260 | 37 | $2,369 |
| Alendronate Sodium Generic | 178 | 399 | 45 | $1,306 |
| Duloxetine Hcl Generic | 176 | 331 | 37 | $4,564 |
| Enbrel Sureclick Etanercept | 169 | 185 | 17 | $1.4M |
| Humira(Cf) Pen Adalimumab | 163 | 163 | 19 | $1.3M |
| Oxycodone Hcl Generic | 154 | 154 | 22 | $2,497 |
Brand drugs: 1,175 claims; generic drugs: 8,687 claims; opioid claims: 1,777.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Raphael I Kieval $33K ($33K in general payments such as food, travel and fees) from 19 companies. The largest payer was Abbvie Inc. with $16K.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 57 | $16K |
| Janssen Biotech, Inc. JNJ | 26 | $13K |
| Amgen Inc. AMGN | 32 | $791 |
| UCB, Inc. UCB.BR | 26 | $526 |
| Pfizer Inc. PFE | 20 | $404 |
| AstraZeneca Pharmaceuticals LP AZN | 13 | $389 |
| Sandoz Inc. SDZ.SW | 14 | $381 |
| Mallinckrodt Hospital Products Inc. | 12 | $342 |
| E.R. Squibb & Sons, L.L.C. BMY | 11 | $254 |
| Novartis Pharmaceuticals Corporation NVS | 10 | $212 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.